PLAN OF ALLOCATIONPlan of Allocation • January 8th, 2019
AMENDED PLAN OF ALLOCATIONPlan of Allocation • August 2nd, 2022
PLAN OF ALLOCATIONPlan of Allocation • February 28th, 2022
This Plan of Allocation will govern distributions from the net proceeds of the $264,000,000 settlement fund created by the February 27, 2022 Stipulation of Settlement (the “Settlement Agreement”) in In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices, and Antitrust Litigation, Case No. 17-md-2785 (D. Kan.), between Plaintiffs and Defendants Mylan N.V., Mylan Specialty L.P., Mylan Pharmaceuticals Inc., Viatris Inc., and Heather Bresch (collectively, the “Mylan Defendants”). To receive a distribution under this Plan of Allocation, a person or entity must timely submit a Proof of Claim and be an Eligible Claimant. The manner in which payments will be allocated and distributed to Eligible Claimants who timely submit Proofs of Claim is described below.
PLAN OF ALLOCATIONPlan of Allocation • August 5th, 2020
